A Trio Of Strategic VCs Helps To Back Effector Therapeutics With $45 Million
This article was originally published in The Pink Sheet Daily
Executive Summary
Using technology spun out of UCSF, a new company hopes to develop oncology drugs that target effector mechanisms of protein synthesis, thereby affecting multiple oncogenes simultaneously. The San Diego-based biotech also hopes to license out its platform for non-cancer indications, bringing in non-dilutive money.
You may also be interested in...
Effector Selects Lead Cancer Compound, Looks Ahead To Combo Regimens
Leading the way in translation regulation, biotech moves its first candidate into clinical development in solid tumors, but plans quick move also into lymphoma.
Start-Up Quarterly Statistics, Q2 2013
The year might have started off slow for start-up fundraising ($398.7 million in Q1), but during the second quarter of 2013 life science companies rallied and earned a whopping $907.2 million. There were several reverse licensing arrangements as well as alliances involving large molecule-focused start-ups.
Biopharma Dealmaking Quarterly Statistics, Q2 2013
Q2 2013 biopharma financing increased 139% to $11 billion over Q1’s $4.6 billion, thanks mostly to two huge transactions by Valeant to fund its $8.7 billion takeover of ophthalmics player Bausch & Lomb, the company’s largest acquisition to date. Options and antibody-drug conjugates featured prominently in the alliances.